Cyclic peptides for protein–protein interaction targets: Applications to human disease

Critical Reviews in Eukaryotic Gene Expression

Volumn 26, Issue 3, 2016, Pages 199-221

  Rubin, Samuel ^a   Qvit, Nir ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclization; Drug discovery; Peptidomimetic; Rational design; Therapeutic

Indexed keywords

AMYLOID BETA PROTEIN; BACTERIAL DNA; BRAIN DERIVED NEUROTROPHIC FACTOR; CASEIN KINASE II; CELL NUCLEUS RECEPTOR; CYCLOPEPTIDE; CYCLOSPORIN A; ESTROGEN RECEPTOR BETA; EXOENZYME S; GRAMICIDIN S; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRASE; METHYLERYTHRITOL 4 PHOSPHATE; MEVALONATE KINASE; POLO LIKE KINASE; PROTEIN KINASE YES; RAS PROTEIN; SOMATOSTATIN; TRANSACTIVATOR PROTEIN; TYROCIDINE; UNCLASSIFIED DRUG; VASCULOTROPIN; PEPTIDOMIMETIC AGENT;

ANDES VIRUS; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; CANCER INHIBITION; DEGENERATIVE DISEASE; DIAPEDESIS; DNA REPLICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION; NEOPLASM; NERVE DEGENERATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; DRUG DEVELOPMENT;

DRUG DISCOVERY; HUMANS; PEPTIDES, CYCLIC; PEPTIDOMIMETICS;

EID: 84989902469     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukaryotGeneExpr.2016016525     Document Type: Article

References (139)

1. Fontaine F, Overman J, Francois M. Pharmacological manipulation of transcription factor protein-protein interactions: opportunities and obstacles. Cell regeneration (London, England). 2015;4(1):2. PubMed PMID: 25848531. Pubmed Central PMCID: PMC4365538. Epub 2015/04/08. eng.
2. Ryan DP, Matthews JM. Protein-protein interactions in human disease. Curr Opin Struct Biol. 2005 Aug;15(4):441-6. PubMed PMID: 15993577. Epub 2005/07/05. eng.
3. Villoutreix BO, Kuenemann MA, Poyet JL, Bruzzoni-Giovanelli H, Labbe C, Lagorce D, Sperandio O, Miteva MA. Drug-like protein-protein interaction modulators: challenges and opportunities for drug discovery and chemical biology. Mol Inform. 2014 Jun;33(6–7):414–37. PubMed PMID: 25254076. Pubmed Central PMCID: PMC4160817. Epub 2014/09/26. Eng.
4. Meyerkord CI, Fu H. Protein-protein interactions: methods and applications: Humana Pr Inc; 2015.
5. Macarron R. Critical review of the role of HTS in drug discovery. Drug discovery today. 2006;11(7-8):277-9.
6. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 2007;450(7172):1001-9.
7. Erlanson DA, Wells JA, Braisted AC. Tethering: Fragment-based drug discovery. Annu Rev Biophys Biomol Struct. 2004;33:199-223. PubMed PMID: ISI:000222339700012. English.
8. Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nature reviews Drug discovery. 2007;6(3):211-9.
9. Gonzalez-Ruiz D, Gohlke H. Targeting protein-protein interactions with small molecules: challenges and perspectives for computational binding epitope detection and ligand finding. Curr Med Chem. 2006;13(22):2607–25. PubMed PMID: 17017914. Epub 2006/10/05.eng.
10. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, Bernard D, Zhang J, Lu Y, Gu Q, Shah RB, Pienta KJ, Ling X, Kang S, Guo M, Sun Y, Yang D, Wang S. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3933–8. PubMed PMID: 18316739. Pubmed Central PMCID: PMC2268798. Epub 2008/03/05. eng.
11. Qvit N, Mochly-Rosen D. Highly specific modulators of protein kinase C localization: applications to heart failure. Drug Discov Today Dis Mech. 2010;7(2):e87-e93.
12. Cheng AC, Coleman RG, Smyth KT, Cao Q, Soulard P, Caffrey DR, Salzberg AC, Huang ES. Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol. 2007 Jan;25(1):71–5. PubMed PMID: 17211405. Epub 2007/01/11. eng.
13. Jin L, Wang W, Fang G. Targeting protein-protein interaction by small molecules. Annu Rev Pharmacol Toxicol. 2014;54:435–56. PubMed PMID: 24160698. Epub 2013/10/29. eng.
14. Qvit N, Crapster JA. Peptides that target protein-protein interactions as an anti-parasite strategy. Chimica Oggi/CHEMISTRY today. 2014;32(6):62–6.
15. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nature Revs Drug Discov. 2004 Apr;3(4):301–17. PubMed PMID: 15060526. Epub 2004/04/03. eng.
16. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009 May;157(2):220–33. PubMed PMID: 19459844. Pubmed Central PMCID: PMC2697811. Epub 2009/05/23. eng.
17. Petsalaki E, Russell RB. Peptide-mediated interactions in biological systems: new discoveries and applications. Curr Opin Biotechnol. 2008 Aug;19(4):344–50. PubMed PMID: 18602004. Epub 2008/07/08. eng.
18. London N, Raveh B, Schueler-Furman O. Modeling peptide-protein interactions. Methods Mol Biol. 2012;857:375–98. PubMed PMID: 22323231. Epub 2012/02/11. eng.
19. Klussmann E, Scott J, Aandahl E. Protein-protein interactions as new drug targets: Springer; 2008.
20. Benyamini H, Friedler A. Using peptides to study protein–protein interactions. Future. 2010;2(6):989–1003.
21. Qvit N. Development and therapeutic applications of oligonucleotides and peptides. Chimica Oggi (Chemistry Today). 2011;29(2):4–7.
22. Koshland DE. The key-lock theory and the induced fit theory. Angewandte Chemie (International Edition in English). 1995;33(23–24):2375–8.
23. Pawson T, Nash P. Assembly of cell regulatory systems through protein interaction domains. Science. 2003;300(5618):445.
24. Sato AK, Viswanathan M, Kent RB, Wood CR. Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol. 2006 Dec;17(6):638–42. PubMed PMID: 17049837. Epub 2006/10/20. eng.
25. Brinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH, Slingluff CL, Jr. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27–35) peptide: implications for peptide vaccines. Int J Cancer. 1999 Oct 29;83(3):326–34. PubMed PMID: 10495424. Epub 1999/09/25. eng.
26. Ahn JM, Boyle NA, MacDonald MT, Janda KD. Peptidomimetics and peptide backbone modifications. Mini Rev Med Chem. 2002 Oct;2(5):463–73. PubMed PMID: 12370047. Epub 2002/10/09. eng.
27. Yin H. Constrained peptides as miniature protein structures. ISRN Biochem. 2012;2012:1–15.
28. Sewald N, Jakubke H. Synthesis of special peptides and peptide conjugates. Peptide Chem Biol VCH. 2002:311–34.
29. Qvit N, Reuveni H, Gazal S, Zundelevich A, Blum G, Niv MY, Feldstein A, Meushar S, Shalev DE, Friedler A, Gilon C. Synthesis of a novel macrocyclic library: discovery of an IGF-1R inhibitor. J Combin Chem. 2008 Mar–Apr;10(2):256–66. PubMed PMID: 18271560. Epub 2008/02/15. eng.
30. Qvit N, Hatzubai A, Shalev DE, Friedler A, Ben-Neriah Y, Gilon C. Design and synthesis of backbone cyclic phosphorylated peptides: the IκB model. Biopolymers. 2009;91(2):157–68.
31. Qvit N. Microwave-assisted synthesis of cyclic phosphopeptide on solid support. Chem Biol Drug Des. 2014;85(3):300–5.
32. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001 Mar 1;46(1–3):3–26. PubMed PMID: 11259830.
33. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002 Jun 6;45(12):2615–23. PubMed PMID: 12036371.
34. Tedesco D, Haragsim L. Cyclosporine: a review. J Transplant. 2012;2012:230386. doi: 10.1155/2012/230386.
35. Epub 2012 Jan 4. PMID: 22263104 PMCID: PMC3259474 DOI: 10.1155/2012/230386.
36. Sieber SA, Marahiel MA. Learning from nature’s drug factories: nonribosomal synthesis of macrocyclic peptides. J Bacteriol. 2003 Dec;185(24):7036–43. PubMed PMID: 14645262. Pubmed Central PMCID: PMC296262. Epub 2003/12/04. eng.
37. Joo SH. Cyclic peptides as therapeutic agents and biochemical tools. Biomol Ther (Seoul). 2012 Jan;20(1):19–26. PubMed PMID: 24116270. Pubmed Central PMCID: PMC3792197. Epub 2012/01/01. Eng.
38. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nature Revs Drug Discov. 2003 Dec;2(12):999–1017. PubMed PMID: 14654798. Epub 2003/12/05. eng.
39. Rai U, Thrimawithana TR, Valery C, Young SA. Therapeutic uses of somatostatin and its analogues: Current view and potential applications. Pharmacol Ther. 2015 Aug;152:98–110. PubMed PMID: 25956467. Epub 2015/05/10. eng.
40. Fosgerau K, Hoffmann T. Peptide therapeutics: Current status and future directions. Drug discovery today. 2015;20(1):122-8.
41. Schwarze SR, Dowdy SF. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci. 2000 Feb;21(2):45–8. PubMed PMID: 10664605. Epub 2000/02/09. eng.
42. Survase SA, Kagliwal LD, Annapure US, Singhal RS. Cyclosporin A—a review on fermentative production, downstream processing and pharmacological applications. Biotechnology advances. 2011 7//;29(4):418–35.
43. Wenger, R. Chemistry of cyclosporine. in: DJG White (Ed.) Cyclosporin A. Elsevier Biomedical Press, Amsterdam; 1982:19–34.
44. Dreyfuss M, Harri E, Hofmann H, Kobel H, Pache W, Tscherter H. Cyclosporin A and C new metabolites from Trichoderma polysporum (Link expers.) Rifai Eur J Appl Microbiol. 1976;3(2):125–33. PubMed PMID: WOS:A1976CN82600006. English.
45. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976 Jul;6(4):468–75. PubMed PMID: 8969. Epub 1976/07/01. eng.
46. Wenger RM. Synthesis of cyclosporine. Total syntheses of ‘cyclosporin A’ and ‘cyclosporin H’, two fungal metabolites isolated from the species Tolypocladium inflatum GAMS. Helv Chim Acta. 1984;67(2):502–25.
47. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000 May;47(2–3):119–25. PubMed PMID: 10878286. Epub 2000/07/06. eng.
48. Schultz C. Safety and Efficacy of Cyclosporine in the Treatment of Chronic Dry Eye. Ophthalmol Eye Dis. 2014 06/24, 04/10/received, 05/07/ revised, 05/12/accepted;6:37-42. PubMed PMID: PMC4076204.
49. Tedesco D, Haragsim L. Cyclosporine: a review. J Transplant. 2012;2012:230386. PubMed PMID: 22263104. Pubmed Central PMCID: PMC3259474. Epub 2012/01/21. eng.
50. Dubos RJ, Hotchkiss RD. The production of bactericidal substances by aerobic sporulating bacilli. J Exp Med. 1941 Apr 30;73(5):629–40. PubMed PMID: 19871101. Pubmed Central PMCID: PMC2135154. Epub 1941/04/30. eng.
51. Gause G, Brazhnikova M. Gramicidin S and its use in the treatment of infected wounds. Nature. 1944;154:703.
52. Marques MA, Citron DM, Wang CC. Development of Tyrocidine A analogues with improved antibacterial activity. Bioorg Med Chem. 2007 Nov 1;15(21):6667–77. PubMed PMID: 17728134. Pubmed Central PMCID: PMC2706120. Epub 2007/08/31. eng.
53. Loll PJ, Upton EC, Nahoum V, Economou NJ, Cocklin S. The high resolution structure of tyrocidine A reveals an amphipathic dimer. Biochimica et Biophysica Acta (BBA) -Biomembranes. 2014;1838(5):1199–207.
54. Tamaki M, Ishii R, Kikuchi S, Watanabe E. A novel active analogue of gramicidin S with smaller ring size. J Antibiot. 2005 04//print;58(4):293–5.
55. Mogi T, Kita K. Gramicidin S and polymyxins: the revival of cationic cyclic peptide antibiotics. Cell Mol Life Sci. 2009 Dec;66(23):3821–6. PubMed PMID: 19701717. Epub 2009/08/25. eng.
56. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973 Jan 5;179(4068):77–9. PubMed PMID: 4682131. Epub 1973/01/05. eng.
57. Hernandez C, Simo R. Somatostatin replacement: a new strategy for treating diabetic retino-pathy. Curr Med Chem. 2013;20(26):3251–7. PubMed PMID: 23745546. Epub 2013/06/12. eng.
58. Hernandez C, Simo-Servat O, Simo R. Somatostatin and diabetic retinopathy: current concepts and new therapeutic perspectives. Endocrine. 2014 Jun;46(2):209–14. PubMed PMID: 24627166. Epub 2014/03/15. eng.
59. Narayanan S, Kunz PL. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2016 Feb;30(1):163–77. PubMed PMID: 26614375. Epub 2015/11/29. eng.
60. Gevers TJ, Drenth JP. Somatostatin analogues for treatment of polycystic liver disease. Current opinion in gastroenterology. 2011 May;27(3):294–300. PubMed PMID: 21191289. Epub 2010/12/31. eng.
61. Stevens P, Foulkes RE, Hartford-Beynon JS, Delicata RJ. Systematic review and meta-analysis of the role of somatostatin and its analogues in the treatment of enterocutaneous fistula. Eur J Gastroenterol Hepatol. 2011 Oct;23(10):912–22. PubMed PMID: 21814141. Epub 2011/08/05. eng.
62. Gurusamy KS, Koti R, Fusai G, Davidson BR. Somatostatin analogues for pancreatic surgery. The Cochrane database of systematic reviews. 2012;4:1–83. PubMed PMID: 22696379. Epub 2012/06/15. eng.
63. Boehm BO. The therapeutic potential of somatostatin receptor ligands in the treatment of obesity and diabetes. Expert opinion on investigational drugs. 2003 Sep;12(9):1501–9. PubMed PMID: 12943494. Epub 2003/08/29. eng.
64. Anthony L, Freda PU. From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin. 2009 Dec;25(12):2989–99. PubMed PMID: 19842996. Pubmed Central PMCID: PMC3678951. Epub 2009/10/22. eng.
65. Ben-Shlomo A, Melmed S. Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol. 2008 11/29;286(1–2):192–8. PubMed PMID: PMC2697610.
66. Sawyers C. Targeted cancer therapy. Nature. 2004 Nov 18;432(7015):294–7. PubMed PMID: 15549090. Epub 2004/11/19. eng.
67. Narang AS, Desai DS. Anticancer drug development-unique aspects of pharmaceutical development. In: Pharmaceutical perspectives of cancer therapeutics. Springer; 2009. p. 49–92.
68. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005 May–Jun;55(3):178–94. PubMed PMID: 15890640. Epub 2005/05/14. eng.
69. von Schwarzenberg K, Vollmar AM. Targeting apoptosis pathways by natural compounds in cancer: marine compounds as lead structures and chemical tools for cancer therapy. Cancer Lett. 2013 May 28;332(2):295–303. PubMed PMID: 20673697. Epub 2010/08/03. eng.
70. Alarcon-Vargas D, Ronai Z. p53-Mdm2-the affair that never ends. Carcinogenesis. 2002 Apr;23(4):541–7. PubMed PMID: 11960904. Epub 2002/04/19. eng.
71. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res. 2003 Dec;1(14):1001–8. PubMed PMID: 14707283. Epub 2004/01/07. eng.
72. Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res. 2008 Sep 1;14(17):5318–24. PubMed PMID: 18765522. Pubmed Central PMCID: PMC2676446. Epub 2008/09/04. eng.
73. Nag S, Zhang X, Srivenugopal KS, Wang MH, Wang W, Zhang R. Targeting MDM2-p53 interaction for cancer therapy: are we there yet? Curr Med Chem. 2014;21(5):553–74. PubMed PMID: 24180275. Epub 2013/11/05. eng.
74. Duncan SJ, Gruschow S, Williams DH, McNicholas C, Purewal R, Hajek M, Gerlitz M, Martin S, Wrigley SK, Moore M. Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J Am Chem Soc. 2001 Jan 31;123(4):554–60. PubMed PMID: 11456567. Epub 2001/07/18. eng.
75. Duncan SJ, Cooper MA, Williams DH. Binding of an inhibitor of the p53/MDM2 interaction to MDM2. Chemical Communications. 2003 (3):316–7.
76. Fasan R, Dias RL, Moehle K, Zerbe O, Vrijbloed JW, Obrecht D, Robinson JA. Using a beta-hairpin to mimic an alpha-helix: cyclic peptidomimetic inhibitors of the p53-HDM2 protein-protein interaction. Angew Chem Int Ed Engl. 2004 Apr 13;43(16):2109–12. PubMed PMID: 15083458. Epub 2004/04/15. eng.
77. Cominetti MM, Goffin SA, Raffel E, Turner KD, Ramoutar JC, O’Connell MA, Howell LA, Searcey M. Identification of a new p53/MDM2 inhibitor motif inspired by studies of chlorofusin. Bioorg Med Chem Lett. 2015 Nov 1;25(21):4878–80. PubMed PMID: 26115576. Epub 2015/06/28. eng.
78. Chang YS, Graves B, Guerlavais V, Tovar C, Packman K, To KH, Olson KA, Kesavan K, Gangurde P, Mukherjee A, Baker T, Darlak K, Elkin C, Filipovic Z, Qureshi FZ, Cai H, Berry P, Feyfant E, Shi XE, Horstick J, Annis DA, Manning AM, Fotouhi N, Nash H, Vassilev LT, Sawyer TK. Stapled alpha-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A. 2013 Aug 14;110(36):E3445-54. PubMed PMID: 23946421. Epub 2013/08/16. Eng.
79. Fischer PM. Peptide, peptidomimetic, and small-molecule antagonists of the p53–HDM2 protein–protein interaction. Int J Pept Res Ther. 2006;12(1):3–19.
80. Goncalves V, Gautier B, Coric P, Bouaziz S, Lenoir C, Garbay C, Vidal M, Inguimbert N. Rational design, structure, and biological evaluation of cyclic peptides mimicking the vascular endothelial growth factor. J Med Chem. 2007 Oct 18;50(21):5135–46. PubMed PMID: 17900101. Epub 2007/09/29. eng.
81. Wang L, Gagey-Eilstein N, Broussy S, Reille-Seroussi M, Huguenot F, Vidal M, Liu WQ. Design and synthesis of C-terminal modified cyclic peptides as VEGFR1 antagonists. Molecules (Basel, Switzerland). 2014;19(10):15391–407. PubMed PMID: 25264829. Epub 2014/09/30. eng.
82. Wang L, Wang-Qing L, Broussy S, Gagey-Eilstein N, Reille-Seroussi M, Huguenot F, Vidal M. Inhibition of VEGF/VEGFR1 interaction by a series of C-terminal modified cyclic peptides. Receptors & Clinical Investigation. 2015;2(1):e534.
83. Goncalves V, Gautier B, Garbay C, Vidal M, Inguimbert N. Structure-based design of a bicyclic peptide antagonist of the vascular endothelial growth factor receptors. Journal of peptide science: an official publication of the European Peptide Society. 2008 Jun;14(6):767–72. PubMed PMID: 18044812. Epub 2007/11/30. eng.
84. Rahimi N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Frontiers in bioscience: a journal and virtual library. 2006 01/01;11:818–29. PubMed PMID: PMC1360224.
85. Vicari D, Foy KC, Liotta EM, Kaumaya PT. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J Biol Chem. 2011 Apr 15;286(15):13612–25. PubMed PMID: 21321115. Pubmed Central PMCID: PMC3075706. Epub 2011/02/16. eng.
86. Zilberberg L, Shinkaruk S, Lequin O, Rousseau B, Hagedorn M, Costa F, Caronzolo D, Balke M, Canron X, Convert O, Lain G, Gionnet K, Goncalves M, Bayle M, Bello L, Chassaing G, Deleris G, Bikfalvi A. Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. J Biol Chem. 2003 Sep 12;278(37):35564–73. PubMed PMID: 12837752. Epub 2003/07/03. eng.
87. Hochscherf J, Lindenblatt D, Steinkruger M, Yoo E, Ulucan O, Herzig S, Issinger OG, Helms V, Gotz C, Neundorf I, Niefind K, Pietsch M. Development of a high-throughput screening-compatible assay to identify inhibitors of the CK2alpha/CK2beta interaction. Anal Biochem. 2014 Sep 16;468C:4-14. PubMed PMID: 25233003. Epub 2014/09/19. Eng.
88. Palmisiano ND, Kasner MT. Polo-like kinase and its inhibitors: Ready for the match to start? Am J Hematol. 2015 Nov;90(11):1071–6. PubMed PMID: 26294255. Epub 2015/08/22. eng.
89. Liu X. Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment. Transl Oncol. 2015 Jun;8(3):185–95. PubMed PMID: 26055176. Pubmed Central PMCID: PMC4486469. Epub 2015/06/10. eng.
90. Kumar S, Kim J. PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis. BioMed research international. 2015;2015:705745. PubMed PMID: 26557691. Pubmed Central PMCID: PMC4628734. Epub 2015/11/12. eng.
91. Murugan RN, Park JE, Lim D, Ahn M, Cheong C, Kwon T, Nam KY, Choi SH, Kim BY, Yoon DY, Yaffe MB, Yu DY, Lee KS, Bang JK. Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1. Bioorg Med Chem. 2013 May 1;21(9):2623–34. PubMed PMID: 23498919. Epub 2013/03/19. eng.
92. Norris JD, Fan D, Stallcup MR, McDonnell DP. Enhancement of estrogen receptor transcriptional activity by the coactivator GRIP-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology. J Biol Chem. 1998 Mar 20;273(12):6679–88. PubMed PMID: 9506965. Epub 1998/04/18. eng.
93. Norris JD, Paige LA, Christensen DJ, Chang CY, Huacani MR, Fan D, Hamilton PT, Fowlkes DM, McDonnell DP. Peptide antagonists of the human estrogen receptor. Science. 1999 Jul 30;285(5428):744–6. PubMed PMID: 10426998. Epub 1999/07/31. eng.
94. Leduc AM, Trent JO, Wittliff JL, Bramlett KS, Briggs SL, Chirgadze NY, Wang Y, Burris TP, Spatola AF. Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11273–8. PubMed PMID: 13679575. Pubmed Central PMCID: PMC208747. Epub 2003/09/19. eng.
95. Zhang Z, Lin Z, Zhou Z, Shen HC, Yan SF, Mayweg AV, Xu Z, Qin N, Wong JC, Zhang Z, Rong Y, Fry DC, Hu T. Structure-based design and synthesis of potent cyclic peptides inhibiting the YAP-TEAD protein-protein interaction. ACS Med Chem Lett. 2014 Sep 11;5(9):993–8. PubMed PMID: 25221655. Pubmed Central PMCID: PMC4160762. Epub 2014/09/16. eng.
96. Miranda E, Nordgren IK, Male AL, Lawrence CE, Hoakwie F, Cuda F, Court W, Fox KR, Townsend PA, Packham GK, Eccles SA, Tavassoli A. A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J Am Chem Soc. 2013 Jul 17;135(28):10418-25. PubMed PMID: 23796364. Pubmed Central PMCID: PMC3715890. Epub 2013/06/26. eng.
97. Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, Skelton NJ, Fauber BP, Pan B, Malek S, Stokoe D, Ludlam MJ, Bowman KK, Wu J, Giannetti AM, Starovasnik MA, Mellman I, Jackson PK, Rudolph J, Wang W, Fang G. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5299–304. PubMed PMID: 22431598. Pubmed Central PMCID: PMC3325706. Epub 2012/03/21. eng.
98. Upadhyaya P, Qian Z, Selner NG, Clippinger SR, Wu Z, Briesewitz R, Pei D. Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides. Angew Chem Int Ed Engl. 2015 Jun 22;54(26):7602-6. PubMed PMID: 25950772. Pubmed Central PMCID: PMC4591930. Epub 2015/05/08. eng.
99. Khalin I, Alyautdin R, Kocherga G, Bakar MA. Targeted delivery of brain-derived neurotrophic factor for the treatment of blindness and deafness. International Journal of Nanomedicine. 2015 04/30;10:3245–67. PubMed PMID: PMC4425321.
100. Binder DK, Scharfman HE. Brain-derived neurotrophic factor. growth factors (Chur, Switzerland). 2004;22(3):123–31. PubMed PMID: PMC2504526.
101. O’Leary PD, Hughes RA. Design of potent peptide mimetics of brain-derived neurotrophic factor. J Biol Chem. 2003;278(28):25738–44.
102. Hoogerhout P, Kamphuis W, Brugghe HF, Sluijs JA, Timmermans HAM, Westdijk J, Zomer G, Boog CJP, Hol EM, van den Dobbelsteen GPJM. A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques. PLoS One. 2011;6(4):e19110.
103. Godyn J, Jonczyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol Rep. 2016 Feb;68(1):127–38. PubMed PMID: 26721364. Epub 2016/01/02. eng.
104. Kumar A, Nisha CM, Silakari C, Sharma I, Anusha K, Gupta N, Nair P, Tripathi T, Kumar A. Current and novel therapeutic molecules and targets in Alzheimer’s disease. J Formos Med Assoc. 2016 Jan;115(1):3–10. PubMed PMID: 26220908. Epub 2015/07/30. eng.
105. Satoh T, Aramini JM, Li S, Friedman TM, Gao J, Edling AE, Townsend R, Koch U, Choksi S, Germann MW, Korngold R, Huang Z. Bioactive peptide design based on protein surface epitopes. A cyclic heptapeptide mimics CD4 domain 1 CC’ loop and inhibits CD4 biological function. J Biol Chem. 1997 May 2;272(18):12175–80. PubMed PMID: 9115290. Epub 1997/05/02. eng.
106. Masopust D, Schenkel JM. The integration of T cell migration, differentiation and function. Nat Rev Immunol. 2013 May;13(5):309–20. PubMed PMID: 23598650. Epub 2013/04/20. eng.
107. Anderson ME, Yakovleva T, Hu Y, Siahaan TJ. Inhibition of ICAM-1/LFA-1-mediated heterotypic T-cell adhesion to epithelial cells: design of ICAM-1 cyclic peptides. Bioorg Med Chem Lett. 2004 Mar 22;14(6):1399–402. PubMed PMID: 15006370. Epub 2004/03/10. eng.
108. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002 Apr;2(4):301–10. PubMed PMID: 12001991. Epub 2002/05/11. eng.
109. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol. 2011 Aug;12(8):715–23. PubMed PMID: 21772280. Epub 2011/07/21. eng.
110. Li X, Abdel-Mageed AB, Mondal D, Kandil E. The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers. Thyroid. 2013 Feb;23(2):209–18. PubMed PMID: 23273524. Epub 2013/01/01. eng.
111. Gambhir S, Vyas D, Hollis M, Aekka A, Vyas A. Nuclear factor kappa B role in inflammation associated gastrointestinal malignancies. World J Gastroenterol. 2015 Mar 21;21(11):3174–83. PubMed PMID: 25805923. Pubmed Central PMCID: PMC4363746. Epub 2015/03/26. eng.
112. Amit S, Ben-Neriah Y. NF-kappaB activation in cancer: a challenge for ubiquitination-and proteasome-based therapeutic approach. Semin Cancer Biol. 2003 Feb;13(1):15–28. PubMed PMID: 12507553.
113. Yaron A, Gonen H, Alkalay I, Hatzubai A, Jung S, Beyth S, Mercurio F, Manning AM, Ciechanover A, Ben-Neriah Y. Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase. EMBO J. 1997 Nov 3;16(21):6486–94. PubMed PMID: 9351830.
114. Morais C, Gobe G, Johnson DW, Healy H. The emerging role of nuclear factor kappa B in renal cell carcinoma. Int J Biochem Cell Biol. 2011 Nov;43(11):1537–49. PubMed PMID: 21854869. Epub 2011/08/23. eng.
115. Gamble C, McIntosh K, Scott R, Ho KH, Plevin R, Paul A. Inhibitory kappa B kinases as targets for pharmacological regulation. Br J Pharmacol. 2012 12/01/received 06/20/revised 07/02/accepted;165(4):802–19. PubMed PMID: PMC3312479.
116. Dahabieh MS, Battivelli E, Verdin E. Understanding HIV latency: the road to an HIV cure. Annu Rev Med. 2015;66:407–21. PubMed PMID: 25587657. Pubmed Central PMCID: PMC4381961. Epub 2015/01/15. eng.
117. Looney D, Ma A, Johns S. HIV therapy-the state of art. Curr Top Microbiol Immunol. 2015;389:1–29. PubMed PMID: 25821102. Epub 2015/03/31. eng.
118. Johri MK, Mishra R, Chhatbar C, Unni SK, Singh SK. Tits and bits of HIV Tat protein. Expert Opin Biol Ther. 2011 Mar;11(3):269–83. PubMed PMID: 21204735. Epub 2011/01/06. eng.
119. Debaisieux S, Rayne F, Yezid H, Beaumelle B. The ins and outs of HIV-1 Tat. Traffic (Copenhagen, Denmark). 2012 Mar;13(3):355–63. PubMed PMID: 21951552. Epub 2011/09/29. eng.
120. Fitting S, Booze RM, Mactutus CF. HIV-1 proteins, Tat and gp120, target the developing dopamine system. Curr HIV Res. 2015;13(1):21–42. PubMed PMID: 25613135. Pubmed Central PMCID: PMC4467793. Epub 2015/01/24. eng.
121. Davidson A, Leeper TC, Athanassiou Z, Patora-Komisarska K, Karn J, Robinson JA, Varani G. Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of Tat protein. Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):11931–6. PubMed PMID: 19584251. Pubmed Central PMCID: PMC2715490. Epub 2009/07/09. eng.
122. Lalonde MS, Lobritz MA, Ratcliff A, Chamanian M, Athanassiou Z, Tyagi M, Wong J, Robinson JA, Karn J, Varani G, Arts EJ. Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. PLoS Pathog. 2011;7(5):e1002038.
123. Lingappa JR, Reed JC, Tanaka M, Chutiraka K, Robinson BA. How HIV-1 Gag assembles in cells: putting together pieces of the puzzle. Virus Res. 2014;193:89–107.
124. Freed EO. HIV-1 assembly, release and maturation. Nat Rev Micro. 2015;13(8):484–96.
125. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999 Sep 3;285(5433):1569–72. PubMed PMID: 10477521.
126. Kurrikof KSR, Gestin MPS, Langel UP. Recent in vivo advances in cell-penetrating peptide-assisted drug delivery. Expert opinion on drug delivery. 2015 Dec 3;22:1–15. PubMed PMID: 26634750. Epub 2015/12/05. Eng.
127. Tavassoli A, Lu Q, Gam J, Pan H, Benkovic SJ, Cohen SN. Inhibition of HIV budding by a genetically selected cyclic peptide targeting the Gag-TSG101 interaction. ACS Chem Biol. 2008 Dec 19;3(12):757–64. PubMed PMID: 19053244. Epub 2008/12/05. eng.
128. Grandgenett DP, Pandey KK, Bera S, Aihara H. Multifunctional facets of retrovirus integrase. World J Biol Chem. 2015 Aug 26;6(3):83–94. PubMed PMID: 26322168. Pubmed Central PMCID: PMC4549773. Epub 2015/09/01. eng.
129. Su M, Tan J, Lin CY. Development of HIV-1 integrase inhibitors: recent molecular modeling perspectives. Drug discovery today. 2015 Nov;20(11):1337–48. PubMed PMID: 26220090. Epub 2015/07/30. eng.
130. Taha H, Das A, Das S. Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS. Infection and drug resistance. 2015;8:339–52. PubMed PMID: 26491363. Pubmed Central PMCID: PMC4598225. Epub 2015/10/23. eng.
131. Hayouka Z, Hurevich M, Levin A, Benyamini H, Iosub A, Maes M, Shalev DE, Loyter A, Gilon C, Friedler A. Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein. Bioorg Med Chem. 2010 Oct 1;18(23):8388–95. PubMed PMID: 20974536. Epub 2010/10/27. Eng.
132. Gimenez-Oya V, Villacanas O, Obiol-Pardo C, Antolin-Llovera M, Rubio-Martinez J, Imperial S. Design of novel ligands of CDP-methylerythritol kinase by mimicking direct protein-protein and solvent-mediated interactions. J Mol Recognit. 2011 Jan–Feb;24(1):71–80. PubMed PMID: 20213667. Epub 2010/03/10. eng.
133. Glas A, Bier D, Hahne G, Rademacher C, Ottmann C, Grossmann TN. Constrained peptides with target-adapted cross-links as inhibitors of a pathogenic protein-protein interaction. Angew Chem Int Ed Engl. 2014 Feb 6;53(9):2489–93. PubMed PMID: 24504455. Epub 2014/02/08. Eng.
134. Kjelstrup S, Hansen PMP, Thomsen LE, Hansen PR, Løbner-Olesen A. Cyclic peptide inhibitors of the β-sliding clamp in Staphylococcus aureus. PLoS One. 2013;8(9):e72273.
135. Hall PR, Malone L, Sillerud LO, Ye C, Hjelle BL, Larson RS. Characterization and NMR solution structure of a novel cyclic pentapeptide inhibitor of pathogenic hantaviruses. Chem Biol Drug Des. 2007 Mar;69(3):180-90. PubMed PMID: 17441904. Epub 2007/04/20. eng.
136. Souroujon MC, Mochly-Rosen D. Peptide modulators of protein-protein interactions in intracellular signaling. Nat Biotechnol. 1998 Oct;16(10):919–24. PubMed PMID: 9788346.
137. Qvit N, Mochly-Rosen D. Highly specific modulators of protein kinase C localization: applications to heart failure. Drug Discov Today Dis Mech. 2010;7(2):e87–e93.
138. Qvit N, Schechtman D, Peña DA, Berti DA, Soares CO, Miao Q, Liang L, Baron LA, Teh-Poot C, Martínez-Vega P, Ramirez-Sierra MJ, Churchill E, Cunningham AD, Malkovskiy AV, Federspiel NA, et al. Scaffold Proteins LACK and TRACK as Potential Drug Targets in Kinetoplastid Parasites: Development of Inhibitors. International Journal for Parasitology: Drugs and Drug Resistance. 2016;6:74-84.
139. Qvit N, Disatnik MH, Sho J, Mochly-Rosen D. Selective Phosphorylation Inhibitor of Delta Protein Kinase C−Pyruvate Dehydrogenase Kinase Protein−Protein Interactions: Application for Myocardial Injury in Vivo. J Am Chem Soc. 2016;138(24):7626-35.